Incretin Therapies in Obesity-related HFpEF

Inclusion Criteria:

* Diagnosis of heart failure (HF) per the ACC/AHA guidelines with NYHA class II-III symptoms
* Left ventricular ejection fraction \>= 45% within 6 months of recruitment
* At least one of the following: elevated N-terminal pro- B-type natriuretic peptide (NT-proBNP) \>=200 pg/ml (\>=600 pg/ml with concurrent atrial fibrillation), evidence of structural heart disease (left atrial (LA) enlargement with LA volume index \>29 mL/m2 or LA diameter \>=40 mm in males/\>38= mm in females), elevated filling pressures (resting wedge \>15 mmHg or exercise wedge \>25 mmHg, lateral E/e' ratio \>12 or septal E/e' \> 15)
* Body mass index (BMI) \>30 kg/m2
* Stable doses of HF medications within 4 weeks of screening with optimal volume control in the opinion of the investigator.

Exclusion Criteria:

* Acute decompensated HF within 4 weeks of screening
* Major cardiovascular event within 90 days of screening (myocardial infarction, stroke)
* Alternate cause of HFpEF such as cardiac amyloidosis, infiltrative cardiomyopathy, hypertrophic cardiomyopathy, severe valvular disease
* Estimated glomerular fibrilation rate (EGFR) \<15 ml/min/1.73m2 or dialysis dependence
* Poorly controlled diabetes (A1c \> 9.5%) OR any type 1 diabetes mellitis
* History of acute or chronic pancreatitis
* Personal or family history of multiple endocrine neoplasia (MEN) or medullary thyroid cancer
* Clinically significant gastric emptying abnormality
* Medical comorbidities that limit survival
* Inability to comply with the study protocol
* Pregnancy